Published in Drug Week, December 31st, 2004
In these phase II clinical trials, alicaforsen enema produced significant and long-lasting disease improvement, as measured by changes in Disease Activity Index (DAI) scores and other indicators of disease.
In particular, a substantial number of patients treated with alicaforsen enema experienced mucosal healing, as well as decreases in rectal bleeding and in stool frequency; manifestations of the disease that cause considerable discomfort, inconvenience and pain to patients. In all three trials,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.